Le Prise et al.1994(12)12. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-84.
|
Randomized |
41 (chemo) vs 45 |
11 |
0.56 |
(surgery) |
11 |
Bosset et al.1994(3)3. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-7.
|
Randomized |
143 (chemo) vs |
18.6 |
0.78 |
139 (surgery) |
18.6 |
Ancona et al.2001(2)2. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esopagheal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-74.
|
Randomized |
47 (chemo) vs |
25 |
0.01 |
47 (surgery) |
24 |
(only complete pathological response) |
Urba et al.2001(25)25. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-13.
|
Randomized |
50 (chemo) vs |
17.6 |
0.15 |
50 (surgery) |
16.9 |
El Nakadi et al.2001(8)8. El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier S, Limbosch JM, Lambilliotte JP, Gelin M. Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease. World J Surg. 2002;26:72-8.
|
Non-randomized |
38 (surgery) vs |
Unavailable |
0.19 |
61 (radio + chemo) |
21 |
Urschel et al.2002(26)26. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538-43.
|
Meta-analysis of nine |
1116 (total) |
Odds ratio: |
0.016 |
randomized studies |
surgery vs |
0.79 (1st year) |
(3rd year) |
(radio + chemo) |
0.77 (2nd year) |
0.66 (3rd year) |
Makary et al.2003(14)14. Makary MA, Kiernan PD, Sheridan MJ, Tonnesen G, Hetrick V, Vaughan B, Graling P, Elster E. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy. Am Surg. 2003;69:693-700.
|
Non-randomized |
76 (surgery) vs |
17.2 vs |
0.01 |
40 (radio + chemo) |
35.7 |
Liao et al.2004(13)13. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004;60:1484-93.
|
Non-randomized |
72 (surgical) vs |
12 vs |
<0.05 |
60 (radio + chemo) |
62 |
Malaisrie et al.2004(15)15. Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Arch Surg. 2004;139:532-8.
|
Non-randomized |
65 (surgical) vs |
28.7 vs |
0.14 |
31 (radio + chemo) |
24.1 |
Fiorica et al.2004(9)9. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-30.
|
Meta analysis of six |
390 (surgery) vs |
Odds ratio: |
0.03 |
randomized studies |
388 (radio + chemo) |
0.53 (3rd year) |
(3rd year) |
Greer et al.2005(10)10. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172-7.
|
Meta-analysis |
364 (surgery) vs |
Odds ratio: |
0.74 |
(6 randomized studies) |
374 (radio + chemo) |
0.86 |
Zhang et al.2005(29)29. Zhang X, Watson DI, Jamieson GG, Bessell JR, Devitt PG. Neoadjuvant chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2005;18:104-8.
|
Non-randomized |
59 (surgery) vs |
19.3% (4 years) vs |
<0.05 |
56 (radio + chemo) |
33.3% (4 years) |
Morgan et al.2007(18)18. Morgan MA, Lewis WG, Crosby TD, Escofet X, Roberts SA, Brewster AE, Harvard TJ, Clark GW. Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer. Br J Surg. 2007:94:1509-14.
|
Non-randomized |
117 (chemo) vs |
24 vs |
0.03 |
88 (radio + chemo) |
43 |
Andreollo et al.2012 |
Non-randomized |
23 (surgery) vs |
32.4 |
0.05 |
71 (radio) vs |
65.4 |
16 (radio + chemo) |
87.2 |